Fatty Liver Disease
Conditions
Keywords
MAFLD
Brief summary
To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China
Detailed description
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease all over the world (1). In early 2020, a new definition of MAFLD has been proposed and is becoming increasingly widely accepted. The new diagnostic criteria are based on the histology or imaging of liver biopsies, or even blood biomarker tests indicative of the presence of fatty liver while satisfying any one of the following three conditions: overweight/obesity, type 2 diabetes, or metabolic dysfunction (2). The information on the prevalence of MAFLD is scarce. This study is designed to conduct MAFLD screening in adults with health check-ups at multiple health examination centers across China. The primary objective is to investigate the prevalence of MAFLD among adults in China.
Interventions
DIAGNOSTIC_TESTFibrotouch
Fibrotouch will be performed showing the stiffness and fat content of liver
Sponsors
Beijing Tsinghua Chang Gung Hospital
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Aged between 18 and 75, both sex; * Able to sign informed consent.
Exclusion criteria
* Pregnant women and those who are implanted with pacemakers, stents or any other metal devices.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To investigate the prevalence of MAFLD among adults at multiple health examination centers across China. | through study completion, an average of 1 year | MAFLD means metabolic dysfunction-associated fatty liver disease |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To assess the proportion of overweight or obese patients with MAFLD (BMI≥23 kg/m²). | through study completion, an average of 1 year | MAFLD means metabolic dysfunction-associated fatty liver disease; BMI means body mass index |
| To assess the prevalence of metabolic dysfunction among patients with MAFLD who are lean or normal in body weight (BMI < 23 kg/m²) | through study completion, an average of 1 year | MAFLD means metabolic dysfunction-associated fatty liver disease; BMI means body mass index |
| To assess the prevalence of type 2 diabetes among patients with MAFLD. | through study completion, an average of 1 year | MAFLD means metabolic dysfunction-associated fatty liver disease |
| To assess the prevalence of liver fibrosis and cirrhosis among patients with MAFLD. | through study completion, an average of 1 year | MAFLD means metabolic dysfunction-associated fatty liver disease |
Countries
China
Contacts
Primary ContactLai Wei, MD
Backup ContactMing Yang, MD
Outcome results
None listed